Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • Preserving Capital Beyond Peak Earning Years for Long-Term Financial Security

    Peak earning years may create wealth, but long-term financial security depends on how that wealth is structured, sustained, and ultimately, transferred.

    Read more

  • Economics Weekly: The Curious Case of Quality

    In this Economics Weekly, we discuss the curious case of quality stocks, why they have suffered, and why we think now is an attractive time for investors to recast their attention to this part of the market.

    Read more

  • How AI is Transforming Health Literacy and Engagement

    AI tools help patients better understand coverage and costs, choose the right providers, and stay on track with care while reducing administrative burden for providers and payers.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures